Milano: una visión futura para un UAS táctico

Proceeding of: VI Congreso Nacional de i+d en Defensa y Seguridad (DESEI+D 2018), Valladolid, 20-22 de noviembre de 2018En este artículo se presenta el nuevo sistema de aeronaves no tripuladas Milano, del Instituto Nacional de Técnica Aeroespacial (INTA). Con una autonomía de vuelo de 20 horas, una carga útil de hasta 150 Kg, y un sistema de comunicaciones radio TCP/IP, el sistema desarrollado posibilita misiones de observación y vigilancia que van más allá de las ofrecidas por un sistema táctico tradicional. En el artículo se identifican las principales características del sistema Milano, en particular las relativas a su sistema de comunicaciones en línea de vista radioeléctrica basado en el protocolo IP. Asimismo, se describen las líneas actuales de trabajo consideradas para la evolución de este sistema: 1) mecanismos de vuelo cooperativo; 2) nuevas evoluciones del sistema de comunicaciones radio en línea de vista; 3) desarrollo de mecanismos para la distribución segura de la información de tele-medida de las aeronaves; y 4) estudio de nuevos enfoques disruptivos para favorecer el despliegue flexible de servicios de telecomunicaciones sobre la plataforma de comunicaciones del Milano.El trabajo realizado por Víctor Sánchez y Borja Nogales ha sido parcialmente financiado por la Unión Europea, mediante el proyecto del H2020 5GinFIRE (grant agreement 732497), y por el Ministerio de Economía y Competitividad, a través del proyecto 5GCITY (TEC2016-76795-C6-3-R)

Experimental evaluation of the interference effect on IEEE 802.11n networks performance

Ingeniería de Telecomunicació

Prosthetic Valve Candida spp. Endocarditis: New Insights Into Long-term Prognosis—The ESCAPE Study

International audienceBackground: Prosthetic valve endocarditis caused by Candida spp. (PVE-C) is rare and devastating, with international guidelines based on expert recommendations supporting the combination of surgery and subsequent azole treatment.Methods: We retrospectively analyzed PVE-C cases collected in Spain and France between 2001 and 2015, with a focus on management and outcome.Results: Forty-six cases were followed up for a median of 9 months. Twenty-two patients (48%) had a history of endocarditis, 30 cases (65%) were nosocomial or healthcare related, and 9 (20%) patients were intravenous drug users. "Induction" therapy consisted mainly of liposomal amphotericin B (L-amB)-based (n = 21) or echinocandin-based therapy (n = 13). Overall, 19 patients (41%) were operated on. Patients <66 years old and without cardiac failure were more likely to undergo cardiac surgery (adjusted odds ratios [aORs], 6.80 [95% confidence interval [CI], 1.59-29.13] and 10.92 [1.15-104.06], respectively). Surgery was not associated with better survival rates at 6 months. Patients who received L-amB alone had a better 6-month survival rate than those who received an echinocandin alone (aOR, 13.52; 95% CI, 1.03-838.10). "Maintenance" fluconazole therapy, prescribed in 21 patients for a median duration of 13 months (range, 2-84 months), led to minor adverse effects.Conclusion: L-amB induction treatment improves survival in patients with PVE-C. Medical treatment followed by long-term maintenance fluconazole may be the best treatment option for frail patients

Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

10.1161/CIRCULATIONAHA.118.038840CIRCULATION1402103-11

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

10.1161/CIRCULATIONAHA.119.042551CIRCULATION140191578-158

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

International audienceBackground: Guidelines recommend nonstatin lipid-lowering agents in patients at very high risk for major adverse cardiovascular events (MACE) if low-density lipoprotein cholesterol (LDL-C) remains ≥70 mg/dL on maximum tolerated statin treatment. It is uncertain if this approach benefits patients with LDL-C near 70 mg/dL. Lipoprotein(a) levels may influence residual risk.Objectives: In a post hoc analysis of the ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, the authors evaluated the benefit of adding the proprotein subtilisin/kexin type 9 inhibitor alirocumab to optimized statin treatment in patients with LDL-C levels near 70 mg/dL. Effects were evaluated according to concurrent lipoprotein(a) levels.Methods: ODYSSEY Outcomes compared alirocumab with placebo in 18,924 patients with recent acute coronary syndromes receiving optimized statin treatment. In 4,351 patients (23.0%), screening or randomization LDL-C was 13.7 mg/dL or ≤13.7 mg/dL; corresponding adjusted treatment hazard ratios were 0.82 (95% CI: 0.72-0.92) and 0.89 (95% CI: 0.75-1.06), with Pinteraction = 0.43.Conclusions: In patients with recent acute coronary syndromes and LDL-C near 70 mg/dL on optimized statin therapy, proprotein subtilisin/kexin type 9 inhibition provides incremental clinical benefit only when lipoprotein(a) concentration is at least mildly elevated. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402)